Europe — EMA
Otulfi (Ustekinumab)
Ustekinumab, the active ingredient in Otulfi, is a monoclonid presented as a / for subcutaneous injection use. It treats moderate to severe plaque psoriasis and psoriatic arthritis in adults.
Request sourcing
What is Ustekinumab?
Ustekinumab, the active ingredient in Otulfi, is a monoclonid presented as a / for subcutaneous injection use. It treats moderate to severe plaque psoriasis and psoriatic arthritis in adults.
GNH USA supplies Otulfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Ustekinumab used for?
Ustekinumab is a biologic therapy that modulates key immune pathways involved in several chronic inflammatory diseases.
- Plaque psoriasis: reduces skin lesions and improves quality of life. - Psoriatic arthritis: alleviates joint inflammation and slows radiographic progression. - Crohn's disease: induces remission in patients with moderate‑to‑high severity. - Ulcerative colitis: helps achieve clinical remission. - Hidradenitis suppurata : provides symptom relief for moderate cases. - Ankylosing spinae l un un un un un un
What are the side effects of Ustekinumab?
Ustekin
